2022 Q2 Form 10-Q Financial Statement
#000095017022014815 Filed on August 04, 2022
Income Statement
Concept | 2022 Q2 | 2022 Q1 | 2021 Q4 |
---|---|---|---|
Revenue | $3.693M | $2.571M | $367.0K |
YoY Change | 139.03% | 182.53% | |
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $7.576M | $6.452M | $9.717M |
YoY Change | 15.56% | 11.63% | 56.47% |
% of Gross Profit | |||
Research & Development | $16.51M | $31.68M | $28.60M |
YoY Change | -32.76% | 38.51% | 1.84% |
% of Gross Profit | |||
Depreciation & Amortization | $600.0K | $676.0K | $728.0K |
YoY Change | -25.0% | -8.77% | -0.27% |
% of Gross Profit | |||
Operating Expenses | $24.09M | $38.13M | $38.32M |
YoY Change | -22.58% | 33.08% | 11.74% |
Operating Profit | -$20.39M | -$35.56M | |
YoY Change | -31.02% | 28.18% | |
Interest Expense | $212.0K | $86.00K | $44.00K |
YoY Change | 190.41% | -21.82% | -83.7% |
% of Operating Profit | |||
Other Income/Expense, Net | $304.0K | -$91.00K | $132.0K |
YoY Change | -202.01% | -1010.0% | -169.47% |
Pretax Income | -$19.88M | -$35.56M | -$37.77M |
YoY Change | -33.28% | 28.71% | 10.44% |
Income Tax | $47.00K | $53.00K | -$58.00K |
% Of Pretax Income | |||
Net Earnings | -$19.92M | -$35.62M | -$37.71M |
YoY Change | -33.18% | 28.69% | 9.57% |
Net Earnings / Revenue | -539.51% | -1385.26% | -10276.29% |
Basic Earnings Per Share | -$0.47 | -$0.84 | |
Diluted Earnings Per Share | -$467.0K | -$837.8K | -$898.6K |
COMMON SHARES | |||
Basic Shares Outstanding | 42.67M | 42.51M | |
Diluted Shares Outstanding | 42.67M | 42.51M |
Balance Sheet
Concept | 2022 Q2 | 2022 Q1 | 2021 Q4 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $159.3M | $183.2M | $190.7M |
YoY Change | -16.42% | -14.14% | -21.67% |
Cash & Equivalents | $71.17M | $104.6M | $186.8M |
Short-Term Investments | $88.17M | $78.66M | $3.918M |
Other Short-Term Assets | $8.320M | $10.30M | $13.53M |
YoY Change | 43.55% | 60.86% | 127.56% |
Inventory | |||
Prepaid Expenses | |||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $167.7M | $195.1M | $204.4M |
YoY Change | -14.73% | -11.25% | -18.24% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $5.781M | $6.018M | $6.180M |
YoY Change | -16.88% | -58.5% | -22.82% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | $0.00 | $0.00 | $15.11M |
YoY Change | |||
Other Assets | $616.0K | $616.0K | $866.0K |
YoY Change | -58.41% | 208.0% | 129.71% |
Total Long-Term Assets | $14.84M | $15.39M | $30.95M |
YoY Change | -2.6% | 4.72% | 102.45% |
TOTAL ASSETS | |||
Total Short-Term Assets | $167.7M | $195.1M | $204.4M |
Total Long-Term Assets | $14.84M | $15.39M | $30.95M |
Total Assets | $182.5M | $210.5M | $235.4M |
YoY Change | -13.85% | -10.25% | -11.28% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $2.762M | $3.755M | $3.015M |
YoY Change | 73.38% | 34.11% | -8.99% |
Accrued Expenses | $12.82M | $19.24M | $25.39M |
YoY Change | -32.72% | 43.57% | 53.31% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $138.0K | $138.0K | $138.0K |
YoY Change | 430.77% | 38.0% | |
Total Short-Term Liabilities | $31.65M | $41.36M | $38.96M |
YoY Change | 5.17% | 64.11% | 28.68% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $334.0K | $365.0K | $394.0K |
YoY Change | -15.87% | 265.0% | -21.2% |
Other Long-Term Liabilities | $133.0K | $134.0K | $133.0K |
YoY Change | -50.19% | -99.04% | -64.91% |
Total Long-Term Liabilities | $133.0K | $134.0K | $133.0K |
YoY Change | -50.19% | -99.05% | -64.91% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $31.65M | $41.36M | $38.96M |
Total Long-Term Liabilities | $133.0K | $134.0K | $133.0K |
Total Liabilities | $45.54M | $57.58M | $50.64M |
YoY Change | 5.93% | 46.52% | 11.88% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$358.6M | -$338.7M | -$303.1M |
YoY Change | 54.44% | 73.5% | |
Common Stock | $495.5M | $491.4M | $487.4M |
YoY Change | 23.46% | 23.39% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $137.0M | $152.9M | $184.7M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $182.5M | $210.5M | $235.4M |
YoY Change | -13.85% | -10.25% | -11.28% |
Cashflow Statement
Concept | 2022 Q2 | 2022 Q1 | 2021 Q4 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$19.92M | -$35.62M | -$37.71M |
YoY Change | -33.18% | 28.69% | 9.57% |
Depreciation, Depletion And Amortization | $600.0K | $676.0K | $728.0K |
YoY Change | -25.0% | -8.77% | -0.27% |
Cash From Operating Activities | -$25.04M | -$20.43M | -$37.48M |
YoY Change | 8.78% | -31.42% | 90.45% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$334.0K | $515.0K | -$336.0K |
YoY Change | 124.16% | 67.75% | 460.0% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$9.642M | -$59.89M | -$16.14M |
YoY Change | -196.42% | -698.89% | -207.62% |
Cash From Investing Activities | -$9.976M | -$60.40M | -$16.48M |
YoY Change | -201.27% | -723.17% | -210.3% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 83.00K | -21.00K | 552.0K |
YoY Change | -10.75% | -126.92% | -99.71% |
NET CHANGE | |||
Cash From Operating Activities | -25.04M | -20.43M | -37.48M |
Cash From Investing Activities | -9.976M | -60.40M | -16.48M |
Cash From Financing Activities | 83.00K | -21.00K | 552.0K |
Net Change In Cash | -34.93M | -80.86M | -53.41M |
YoY Change | 167.24% | 303.79% | -128.32% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$25.04M | -$20.43M | -$37.48M |
Capital Expenditures | -$334.0K | $515.0K | -$336.0K |
Free Cash Flow | -$24.70M | -$20.95M | -$37.14M |
YoY Change | 8.03% | -30.41% | 89.32% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-63000 | ||
CY2021Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
164000 | |
CY2021Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2022Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2022Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001799448 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-06-30 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-39617 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
Aligos Therapeutics, Inc. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
82-4724808 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
One Corporate Drive | ||
dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
2nd Floor | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
South San Francisco | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
94080 | ||
dei |
City Area Code
CityAreaCode
|
800 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
466-6059 | ||
dei |
Security12b Title
Security12bTitle
|
Common Stock, par value, $0.0001 per share | ||
CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
50638000 | |
us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
309000 | ||
CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
42690229 | |
CY2022Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | |
CY2022Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5965000 | ||
CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | |
CY2022Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
495538000 | |
CY2022Q2 | us-gaap |
Short Term Investments
ShortTermInvestments
|
88172000 | |
CY2021Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
3918000 | |
CY2022Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2021Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
487347000 | |
CY2022Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-358611000 | |
CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-303072000 | |
CY2022Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2022Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
50000 | |
CY2022Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2021Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
452000 | |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
136981000 | |
CY2022Q2 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
8320000 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
184731000 | |
CY2022Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
182523000 | |
CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
235369000 | |
CY2021Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
13526000 | |
algs |
Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
|
126000 | ||
CY2022Q2 | us-gaap |
Assets Current
AssetsCurrent
|
167685000 | |
CY2022Q2 | us-gaap |
Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
|
3693000 | |
CY2021Q2 | us-gaap |
Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
|
1545000 | |
us-gaap |
Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
|
6264000 | ||
CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
204424000 | |
CY2022Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
320000000 | |
us-gaap |
Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
|
2455000 | ||
CY2022Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
8441000 | |
CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
8789000 | |
CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
320000000 | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
849000 | ||
CY2022Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
16510000 | |
us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-63000 | ||
CY2022Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
5781000 | |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
6180000 | |
CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
38957000 | |
CY2022Q2 | us-gaap |
Long Term Investments
LongTermInvestments
|
0 | |
CY2021Q4 | us-gaap |
Long Term Investments
LongTermInvestments
|
15110000 | |
CY2022Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
616000 | |
CY2021Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
866000 | |
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
15000 | ||
CY2022Q2 | us-gaap |
Assets
Assets
|
182523000 | |
CY2021Q4 | us-gaap |
Assets
Assets
|
235369000 | |
CY2022Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2762000 | |
CY2022Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
10302000 | |
CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
11287000 | |
CY2022Q2 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
201000 | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
459000 | ||
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-61000 | ||
us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
626000 | ||
CY2022Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
42808288 | |
dei |
Trading Symbol
TradingSymbol
|
ALGS | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
287000 | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | ||
dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2022Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
71172000 | |
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
186816000 | |
CY2022Q2 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
21000 | |
CY2022Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
42808288 | |
CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
42690229 | |
CY2021Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3015000 | |
us-gaap |
Depreciation
Depreciation
|
1246000 | ||
CY2022Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
12824000 | |
CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
25394000 | |
CY2022Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2796000 | |
CY2021Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2769000 | |
CY2022Q2 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
138000 | |
CY2021Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
138000 | |
CY2022Q2 | algs |
Deferred Revenue From Collaboration Current
DeferredRevenueFromCollaborationCurrent
|
13133000 | |
CY2022Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
47000 | |
CY2021Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
28000 | |
CY2021Q4 | algs |
Deferred Revenue From Collaboration Current
DeferredRevenueFromCollaborationCurrent
|
7641000 | |
CY2022Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
31653000 | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
99000 | ||
CY2021Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
261000 | |
CY2022Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
133000 | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
74000 | ||
CY2021Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
133000 | |
CY2022Q2 | algs |
Deferred Revenue From Collaboration Non Current
DeferredRevenueFromCollaborationNonCurrent
|
3253000 | |
CY2022Q2 | us-gaap |
Liabilities
Liabilities
|
45542000 | |
CY2021Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
24554000 | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
48186000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
47422000 | ||
CY2022Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7576000 | |
CY2021Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6556000 | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
14028000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
12337000 | ||
CY2022Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
24086000 | |
CY2021Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
31110000 | |
CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-154000 | |
us-gaap |
Operating Expenses
OperatingExpenses
|
62214000 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
59759000 | ||
CY2022Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-20078000 | |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19924000 | |
CY2022Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-20393000 | |
CY2021Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-29565000 | |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
136981000 | |
CY2021Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-29842000 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-55950000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-57304000 | ||
CY2022Q2 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
516000 | |
CY2021Q2 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
-225000 | |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
152886000 | |
CY2022Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1000 | |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-55941000 | ||
us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
510000 | ||
us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
-114000 | ||
CY2022Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-19877000 | |
CY2021Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-29790000 | |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-55440000 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-57418000 | ||
CY2021Q2 | us-gaap |
Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
|
2000 | |
us-gaap |
Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
|
3000 | ||
CY2022Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
111000 | |
CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
|
3554000 | |
CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-154000 | |
CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
447000 | |
CY2021Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-24000 | |
CY2022Q2 | algs |
Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
|
60000 | |
us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-402000 | ||
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19924000 | |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-29818000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-55539000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-57492000 | ||
CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-154000 | |
CY2021Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-26000 | |
us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-402000 | ||
us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-66000 | ||
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-57555000 | ||
CY2022Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.47 | |
CY2021Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.79 | |
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.30 | ||
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.53 | ||
CY2022Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
42665598 | |
CY2021Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
37619039 | |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
42590479 | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
37526650 | ||
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
184731000 | |
us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
11000 | ||
us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
111000 | ||
us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
|
7034000 | ||
us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
891000 | ||
algs |
Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
|
144000 | ||
us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-402000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-55539000 | ||
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
136981000 | |
CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
195220000 | |
CY2021Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
213000 | |
CY2021Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3209000 | |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-29818000 | |
CY2021Q2 | algs |
Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
|
84000 | |
CY2021Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-24000 | |
us-gaap |
Depreciation
Depreciation
|
1511000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-57492000 | ||
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
168884000 | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
220943000 | |
CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
71193000 | |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
168884000 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
220039000 | |
CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
187843000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-55539000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-57492000 | ||
CY2022Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
71172000 | |
CY2021Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
187650000 | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-70380000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7786000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
6205000 | ||
us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-5595000 | ||
us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
221000 | ||
algs |
Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
|
278000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-253000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1834000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-12425000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
1862000 | ||
algs |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-957000 | ||
algs |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-626000 | ||
us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-112000 | ||
us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
8745000 | ||
us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-2455000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-45469000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-52814000 | ||
us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
5245000 | ||
us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
10000000 | ||
us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
74776000 | ||
us-gaap |
Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
|
10000000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
19541000 | ||
us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
111000 | ||
algs |
Payments On Deferred Offering Costs
PaymentsOnDeferredOfferingCosts
|
99000 | ||
us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
60000 | ||
us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
37000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
11000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
309000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
62000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
173000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-115787000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-33100000 | ||
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
186980000 | |
CY2022Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
21000 | |
CY2021Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
193000 | |
CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
71193000 | |
CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
187843000 | |
algs |
Market To Market Adjustments For Available For Sale Investments
MarketToMarketAdjustmentsForAvailableForSaleInvestments
|
-402000 | ||
algs |
Market To Market Adjustments For Available For Sale Investments
MarketToMarketAdjustmentsForAvailableForSaleInvestments
|
-66000 | ||
us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
184000 | ||
algs |
Vesting Of Early Exercised Options Value
VestingOfEarlyExercisedOptionsValue
|
144000 | ||
algs |
Vesting Of Early Exercised Options Value
VestingOfEarlyExercisedOptionsValue
|
126000 | ||
algs |
Change In Pension Obligation
ChangeInPensionObligation
|
3000 | ||
CY2022Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-358600000 | |
CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-303100000 | |
CY2022Q2 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
159300000 | |
algs |
Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
|
637000 | ||
us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Organization </span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Aligos Therapeutics, Inc. (Aligos-US) was incorporated in the state of Delaware on February 5, 2018 (inception). On September 10, 2018, the Company formed Aligos Belgium BVBA (Aligos-Belgium), a limited liability company organized under the laws of Belgium. On March 30, 2020, the Company formed as a wholly owned subsidiary, Aligos Australia Pty LTD (Aligos-Australia), a proprietary limited company. On May 18, 2021, the Company formed as a wholly owned subsidiary, Aligos Therapeutics (Shanghai) Co. Ltd. (Aligos-Shanghai) and together with Aligos-US, Aligos-Belgium, and Aligos-Australia being the “Company” or “Aligos”.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Aligos is a clinical-stage biopharmaceutical company developing novel therapeutics to address unmet medical needs in viral and liver diseases, including for chronic hepatitis B, coronaviruses and non-alcoholic steatohepatitis (NASH).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is devoting substantially all of its efforts to the research and development of its drug candidates. The Company has not generated any product revenue to date. The Company is also subject to a number of risks similar to other companies in the biotechnology industry, including the uncertainty of success of its nonclinical studies and clinical trials, regulatory approval of drug candidates, uncertainty of market acceptance of products, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, dependence on third-parties, product liability, and dependence on key individuals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial public offering</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On October 20, 2020, the Company closed its initial public offering (IPO) at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share for net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">135.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions. On November 5, 2020, the underwriters of the IPO partially exercised their overallotment, resulting in an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">16.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million in net proceeds, after deducting underwriting discounts and commissions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred losses and negative cash flows from operations since its inception. As of June 30, 2022 and December 31, 2021, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">358.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">303.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of expanded research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2022, the Company has unrestricted cash, cash equivalents and investments of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">159.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> which is available to fund future operations. The Company expects to continue to spend substantial amounts to continue the nonclinical and clinical development of its current and future programs. If the Company is able to gain marketing approval for drug candidates that are being developed, it will require significant additional amounts of cash in order to launch and commercialize such drug candidates. In addition, other unanticipated costs may arise. Because the design and outcome of the Company’s planned and anticipated clinical trials is highly uncertain, the Company cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any drug candidate the Company may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to finance its cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. In addition, the Company may seek additional capital to take advantage of favorable market conditions or strategic opportunities even if the Company believes it has sufficient funds for its current or future operating plans. Based on the Company’s research and development plans, the Company expects its existing unrestricted cash, cash equivalents and investments, will enable it to fund its operations for at least 12 months following the date the condensed consolidated financial statements are issued. However, the Company’s operating plan may change as a result of many factors currently unknown, and the Company may need to seek additional funds sooner than planned. Moreover, it is particularly difficult to estimate with certainty the Company’s future expenses given the dynamic nature of its business, the COVID-19 pandemic and the macro-economic environment generally.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company’s ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond its control. For example, the COVID-19 pandemic, the current inflationary economic environment and rising interest rates have resulted in a disruption of global financial markets. If the disruption persists or deepens, the Company could be unable to access additional capital, which could negatively affect its ability to consummate certain corporate development transactions or other important, beneficial or opportunistic investments. If additional funds are not available to the Company when needed, on terms that are acceptable to the Company, or at all, the Company may be required to: delay, limit, reduce or terminate nonclinical studies, clinical trials or other research and development activities or eliminate one or more of its development programs altogether; or delay, limit, reduce or terminate its efforts to establish manufacturing and sales and marketing capabilities or other activities that may be necessary to commercialize any future approved products, or reduce the Company’s flexibility in developing or maintaining its sales and marketing strategy.</span></p> | ||
CY2022Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
14288000 | |
CY2021Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
13442000 | |
CY2022Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
8507000 | |
CY2021Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
7262000 | |
CY2022Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
5781000 | |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
6180000 | |
CY2022Q2 | us-gaap |
Depreciation
Depreciation
|
600000 | |
us-gaap |
Depreciation
Depreciation
|
1200000 | ||
CY2021Q2 | us-gaap |
Depreciation
Depreciation
|
800000 | |
us-gaap |
Depreciation
Depreciation
|
1500000 | ||
CY2021Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
19068000 | |
CY2021Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
40000 | |
CY2021Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
19028000 | |
CY2022Q2 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
|
88613000 | |
CY2022Q2 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
88172000 | |
CY2022Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
88613000 | |
CY2022Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
88172000 | |
CY2022Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3200000 | |
CY2021Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
6329000 | |
CY2022Q2 | algs |
Accrued Payables Current
AccruedPayablesCurrent
|
8637000 | |
CY2021Q4 | algs |
Accrued Payables Current
AccruedPayablesCurrent
|
17554000 | |
CY2022Q2 | algs |
Liability For Early Exercised Stocks Options Current
LiabilityForEarlyExercisedStocksOptionsCurrent
|
131000 | |
CY2021Q4 | algs |
Liability For Early Exercised Stocks Options Current
LiabilityForEarlyExercisedStocksOptionsCurrent
|
276000 | |
CY2022Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
856000 | |
CY2021Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1235000 | |
CY2022Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
12824000 | |
CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
25394000 | |
us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | ||
us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | ||
us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
65688 | ||
CY2021 | us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
163855 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
6204000 | ||
CY2021Q4 | us-gaap |
Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
|
0 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-57492000 | ||
CY2022Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
42665598 | |
CY2021Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
37619039 | |
CY2022Q2 | algs |
Aggregate Price For Share Repurchase
AggregatePriceForShareRepurchase
|
100000 | |
CY2021Q4 | algs |
Aggregate Price For Share Repurchase
AggregatePriceForShareRepurchase
|
300000 | |
CY2022Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3994000 | |
CY2021Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3448000 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7780000 | ||
CY2022Q2 | algs |
Expense Related To Milestone Payments
ExpenseRelatedToMilestonePayments
|
0 | |
algs |
Expense Related To Milestone Payments
ExpenseRelatedToMilestonePayments
|
0 | ||
CY2021Q2 | algs |
Expense Related To Milestone Payments
ExpenseRelatedToMilestonePayments
|
0 | |
algs |
Expense Related To Milestone Payments
ExpenseRelatedToMilestonePayments
|
0 | ||
CY2022Q2 | us-gaap |
Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
|
0 | |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19924000 | |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-29818000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-55539000 | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
42590479 | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
37526650 | ||
CY2022Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.47 | |
CY2021Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.79 | |
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.30 | ||
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.53 | ||
CY2022Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9016086 | |
CY2021Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5775012 | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9016086 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5775012 |